Gilead Announces Results From Studies Evaluating Sofosbuvir-Based Regimens in Chronic Hepatitis C Patients With Genotypes 2-5
Download PDF
November 11, 2014
Gilead Announces Phase 2 Data for Investigational All-Oral Regimen of Sofosbuvir Plus GS-5816 for the Treatment of Chronic Hepatitis C
Download PDF
November 8, 2014
ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients
View Press Release
April 12, 2014
Abbvie to present late-breaking results from TURQUOISE-II study in chronic hepatitis C patients with cirrhosis at the 2014 International Liver Congress
View Press Release
December 18, 2013
Gilead announces SVR12 rates from three phase III studies evaluating a once-daily fixeddose combination of sofosbuvir and ledipasvir for genotype 1 hepatitis C patients
Download the PDF
December 10, 2013
Abbvie demonstrates 96% SVR(12) in its phase III study of treatment-experienced patients with genotype 1 hepatitis C
Download the PDF
December 6, 2013
U.S. Food and Drug Administration approves Gilead’s Sovaldi™ (sofosbuvir) for the treatment of chronic hepatitis C
Download the PDF
November 18, 2013
Abbvie releases first of six phase III results from investigational all-oral, interferon-free, 12- week regimen, showing 96% SVR12 in genotype 1 hepatitis C patients new to therapy